What is Rybelsus 3 mg used for?
Rybelsus 3 mg is the starting dose of Rybelsus (oral semaglutide), a daily tablet approved in India for type 2 diabetes. The US label sets it for the first 30 days to ease stomach side effects. It says 3 mg does not control blood sugar. The label then raises the dose to 7 mg, and to 14 mg if needed.
- GLP‑1 medicines are prescription-only in India, not sold over the counter.7
- A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.7 CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.8,9
- The risks are in Guide 5: Side effects and risks.
- Nothing here promises any result.
Why does Rybelsus start at 3 mg?
Rybelsus starts at 3 mg once a day for 30 days, so your stomach can get used to semaglutide before a dose that works.1
The US label says the 3 mg dose is "not effective for glycemic control". In plain words, it does not lower blood sugar enough to count as treatment.1 The slow start is there to cut the chance of stomach side effects.1
Your doctor sets your dose. We found no public Indian label, so these steps are the US label's. From day 31 it moves to 7 mg. From day 61 it stays at 7 mg, or rises to 14 mg if blood sugar needs more control.1
What is Rybelsus approved for in India?
In India, Rybelsus 3, 7 and 14 mg tablets are approved for type 2 diabetes, and we found no Indian approval for weight loss.2
A CDSCO expert panel reviewed an updated Rybelsus leaflet on 20 August 2025. Medical Dialogues reports the tablets as indicated for type 2 diabetes.2 The US label adds a second use. It lowers the risk of heart attack, stroke and heart-related death in high-risk adults with type 2 diabetes.1 We found no matching Indian approval.
Pharmacies list Rybelsus 3 mg at ₹2,972 to ₹3,170 for a strip of 10. PharmEasy raised its listing to ₹3,170 in October 2026, while Medkart still lists ₹2,971.88, checked 11 October 2026.3 The 30-day starting month takes 3 strips, or ₹8,916 to ₹9,510. How it fits with metformin and other diabetes medicines is on the type 2 diabetes path. Every brand and price is in Guide 6.
Build a list of questions to ask. Free, no sign-up.
What are the newer Rybelsus 1.5 mg, 4 mg and 9 mg tablets?
They are a newer semaglutide tablet that the body absorbs better, so 1.5 mg matches the old 3 mg starting dose.4
A May 2024 letter to doctors in Europe matches 4 mg to 7 mg, and 9 mg to 14 mg. It says the new tablets have the same effect and safety.4 It warned that mixing up the old and new tablets could lead to an overdose.4
In the US, the FDA approved the name Ozempic for these tablets on 4 February 2026. They went on sale there from 4 May 2026.5,6 The US label says the two kinds are "not substitutable on a mg-to-mg basis".1 The Indian pharmacy listing we checked shows only 3, 7 and 14 mg.3 We found no Indian approval of the newer tablets.
- Stomach effects are common. Nausea in 11% on 7 mg and 20% on 14 mg, vs 6% on a dummy tablet (US label).1
- Pancreatitis (a swollen pancreas) has been seen. The label says to stop if it is suspected.1
- Hypos (low blood sugar) are more likely with insulin or a sulfonylurea such as glimepiride.1
- Dehydration from vomiting or diarrhoea can hurt the kidneys. Gallbladder problems are also listed.1
- Thyroid. Ruled out by the US label for anyone with a personal or family history of medullary thyroid cancer or MEN 2; tell your doctor if this applies.1
- Pregnancy. The label says to stop at least 2 months before a planned pregnancy.1
Read the full picture
Related questions
Sources
- Novo Nordisk. Rybelsus and Ozempic (semaglutide) tablets, US prescribing information, revised 1/2026. US label, not the Indian one: we found no public Indian label. Boxed warning; sections 1, 2.2, 2.3, 5.2, 5.4, 5.5, 5.8, 6.1 (Table 2), 8.3. novo-pi.com
- Medical Dialogues. Novo Nordisk gets CDSCO panel nod for Rybelsus label update aligned with EMA (Subject Expert Committee, 20 August 2025; Rybelsus 3, 7 and 14 mg tablets). 10 Sep 2025. medicaldialogues.in
- Rybelsus 3 mg MRP per strip of 10, as listed by PharmEasy (₹2,972; page updated 1 Oct 2026; lists 3, 7 and 14 mg) and Medkart (₹2,971.88). Pharmacy-listed MRP, not a maker announcement. Checked 5 Oct 2026. On 11 Oct 2026, PharmEasy gave the 3 mg MRP as ₹3,170 a strip ("since October 2026"), while Medkart still listed ₹2,971.88. (Pharmacy product pages, not linked.)
- Novo Nordisk with the European Medicines Agency. Direct healthcare professional communication: Rybelsus (oral semaglutide), risk of medication error due to introduction of new formulation with increased bioavailability. 2 May 2024. ema.europa.eu
- Isaacs D, Bellini N. Novo Nordisk rebrands Rybelsus as Ozempic to increase patient awareness. HCPLive, 17 Feb 2026. hcplive.com
- Novo Nordisk. Novo Nordisk's Ozempic pill … soon to be available in the US (press release, PR Newswire), 1 May 2026. prnewswire.com
- Outlook India. Inspections, surveillance to continue against unauthorised sale, promotion of GLP-1 weight-loss drugs: govt, 1 Apr 2026. outlookindia.com
- CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 100th meeting, 20–21 April 2023. Item 1, tirzepatide (Eli Lilly). PDF · archived copy
- CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 13–14 February 2024. Items 3–4, semaglutide (Novo Nordisk). PDF · archived copy
Last checked 5 Oct 2026 · Next review due 5 Apr 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write